A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Oct 2023 Planned End Date changed from 1 Jun 2023 to 30 Dec 2025.
- 04 Oct 2023 Planned primary completion date changed from 1 Jun 2023 to 30 Dec 2025.
- 02 Mar 2022 Status changed from not yet recruiting to recruiting.